Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-rituximab for Relapsed or Refractory DLBCL
NCT01676558Phase 2Unknown
- Sponsor
- Korea Cancer Center Hospital
- Start
- Jun 2012
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iodine-131-rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Korea Cancer Center Hospital. Status: unknown.
02
Drugs
iodine-131-rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01676558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01676558.